Article Details
Retrieved on: 2021-05-20 10:32:32
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
New Phase II data demonstrates that once-monthly treatment with an investigational monoclonal antibody, ziltivekimab, significantly reduced multiple ...
Article found on: www.europeanpharmaceuticalreview.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here